Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens

Annals of Surgical Oncology

Volumn 4, Issue 5, 1997, Pages 416-420

  Calvano, Jacqueline E ^a   Rush, Elisa B ^a   Tan, Lee K ^a   Rosen, Paul Peter ^a   Borgen, Patrick I ^a   Van Zee, Kimberly J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

(CDKN2); Breast carcinoma; Genetic alterations; Microdissection; MTS1; p16

Indexed keywords

CARRIER PROTEIN; DNA; PROTEIN P16INK4A;

AGAR GEL ELECTROPHORESIS; ARTICLE; BREAST TUMOR; FEMALE; GENE DELETION; GENETICS; HUMAN; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; ELECTROPHORESIS, AGAR GEL; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0031182965     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02305555     Document Type: Article

References (13)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
2. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
3. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375:506-10.
4. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
5. Rush EB, Abouezzi Z, Borgen PI, Anelli A. Analysis of MTS1/ CDK4 in female breast carcinomas. Cancer Lett 1995;89:223-6.
6. Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, et al. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res 1994;54:5262-4.
7. Youngson BJ, Anelli A, Van Zee KJ, Borgen PI, Norton L, Rosen PP. Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma. Am J Surg Pathol 1995;19:1354-8.
8. Hussussian Q, Struewing JP, Goldstien AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-20.
9. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995;146:1199-206.
10. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
11. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger P, Baylin SB, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
12. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, Sidransky D, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55: 4525-30.
13. Zulueta-Gonzalez M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.